2024 Annual Report of Journal of Cancer Metastasis and Treatment

The year 2024 marked a significant period of growth and achievement for Journal of Cancer Metastasis and Treatment (JCMT). This success is attributed to the collaborative efforts of the editorial team, authors, reviewers, webinar and conference participants, readers, and editorial staff. Together, they have contributed to JCMT’s remarkable progress and its growing reputation among professionals and academics in relevant sectors. The JCMT Editorial Office is proud to highlight the journal's key achievements in 2024, which are summarized below across five major aspects.

Highlights：

1. A total of 145 submissions were received and 32 papers published;
2. 12 outstanding experts joined the Editorial Board and 33 the Junior Editorial Board;
3. Experts from different countries led 18 Special Issues as Guest Editors;
4. JCMT organized 3 exclusive interviews and 2 webinars;
5. JCMT achieved a CiteScore of 1.4 in 2024.

1. Submissions and Publications

In 2024, JCMT received 145 submissions, of which 32 papers were published, reflecting a rigorous rejection rate of 78%. The journal remains committed to publishing high-quality research and features a diverse range of article types, including Original Articles, Reviews, Commentaries, Editorials, and Interviews (Figure 1).

Figure 1. Distribution of Publication Types

The published articles cover a broad spectrum of key research areas, such as lung adenocarcinoma, the tumor microenvironment, immunotherapy for breast cancer, liver cancer, ovarian cancer, colorectal cancer, etc. These publications have made substantial contributions to their respective fields and have garnered international recognition within the academic community.

The 43 corresponding authors of these publications include influential figures such as Dr. Riccardo Moia from Università del Piemonte Orientale, Dr. Qinghua Zhou from West China Hospital, and Prof. Timothy M. Pawlik from The Ohio State University. As shown in Figure 2, nearly 31% of the corresponding authors have an h-index of 60 or higher and 25% have an h-index between 40 and 60, underscoring the high caliber of contributors to JCMT in 2024 (Figure 2).

Figure 2. Distribution of H-Index of Corresponding Authors for Articles Published in 2024

In the year 2024, a total of 94 reviewers from nine nations or regions made substantial contributions to the peer-review process, with the majority from USA (40%), China (22%), and Italy (13%) (Figure 3). Their meticulous analysis and constructive suggestions played a pivotal role in advancing the quality and impact of articles published in JCMT, significantly enhancing the value of the reviewed publications and expediting the journal's development. The editors of JCMT extend special appreciation to these reviewers for their generous dedication of time and expertise.

Figure 3. Distribution of Reviewers by Country/Region

2. Editorial Board

2.1 New Membership

In 2024, JCMT welcomed 12 distinguished scholars to the Editorial Board (Figure 4):

• Prof. Daxiang Cui, School of Sensing Science and Engineering, Shanghai Jiao Tong University, Shanghai, China
• Prof.Consuelo Amantini, School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy
• Prof. Alfio Wo Ferlito, Coordinator of the International Head and Neck Scientific Group, Padua, Italy
• Prof. Hongyun Zhao, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
• Prof. Gang Guo, Center for Gut Microbiome Research, Med-X Institute Centre, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
• Prof. Dario Marchetti, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, USA
• Prof. William L. Blalock, CNR, Istituto Di Genetica Molecolare “Luigi Luca Cavalli Sforza”, Bologna, Italy
• Prof. Timothy M. Pawlik, Department of Surgery, The Ohio State University College of Medicine, Columbus, USA
• Prof. Pedro Fonte, Centre of Marine Sciences (CCMAR), Campus de Gambelas, Universidade do Algarve, Faro, Portugal
• Prof. Eric A. Singer, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
• Prof. Stergios Boussios, Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, UK
• Prof. Michael Atkins, Division of Hematology/Oncology, MedStar Georgetown University Hospital, Washington, USA

Figure 4. New members joining the Editorial Board in 2024

2.2. Special Issues

In 2024, JCMT collaborated with 26 distinguished scholars to release 18 Special Issues (Figure 5). This initiative created a dynamic community of authors and readers who not only shared their insights but also proposed innovative directions for future research. A full list of ongoing Special Issues can be found at https://www.oaepublish.com/jcmt/ongoing_special_issues.

Figure 5. Covers of Special Issues in 2024

3. Academic Activities

3.1 Exclusive Interviews

Over the past year, we had the honor of interviewing three distinguished experts:

• Prof. Michael Atkins, Division of Hematology/Oncology, MedStar Georgetown University Hospital, Washington, USA (Figure 6)
• Prof. Timothy M. Pawlik, Department of Surgery, The Ohio State University College of Medicine, Columbus, USA (Figure 7)
• Yudong Zhang, School of Computing and Mathematical Sciences, University of Leicester, Leicester, United Kingdom (Figure 8)

Figure 6. Interview with Prof. Michael Atkins

Figure 7. Interview with Prof. Timothy M. Pawlik

Figure 8. Interview with Prof. Yudong Zhang-“Clarivate 2023 Highly Cited Researcher”

3.2 Webinars

To promote academic exchange among experts, JCMT hosted two outstanding webinars in 2024: Applications and Future Prospects of AI in Cancer, chaired by Dr. Pier Paolo Piccaluga and Dr. Ciro Isidoro (Figure 9), and Navigating the Landscape of Metastatic Brain Tumors: From Molecular Mechanisms to Cutting-Edge Treatments, chaired by Dr. Kevin Pierre (Figure 10). These sessions attracted considerable attention, with 17,000 views and 15,367 shares online. You can access more presentations by clicking: https://www.oaepublish.com/jcmt/webinars.

During the webinars, experts shared their insights, engaged in insightful discussions, and inspired the audience with new ideas. We extend our heartfelt gratitude to all the experts who contributed to these influential events.

Figure 9. Webinar on Applications and Future Prospects of AI in Cancer

Figure 10. Webinar on Navigating the Landscape of Metastatic Brain Tumors: From Molecular Mechanisms to Cutting-Edge Treatments

4. Collaboration and Conferences

In 2024, JCMT successfully partnered with seven international conferences, including four online collaborations: the 3^rd International Conference on Cancer Science and Therapy (Figure 11), the 12^th ASIA-PACIFIC BREAST CANCER SUMMIT 2024 (Figure 12), the 2^nd International Cancer Science Congress (Figure 13), and the 2^nd Animal Models of Cancer Conference (Figure 14). Additionally, Editor-in-Chief Prof. Ciro Isidoro participated in the 2^nd International Cancer Science Congress (ICSC) 2024 and conducted promotional work for the journal (Figure 15). Editors of JCMT also attended the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) & 4^th International Congress of the Asian Oncology Society (AOS2024) (Figure 16) and 2024 China (Guangxi)-Asian International Cancer Precision Medicine Conference (Figure 17). These events allowed JCMT to gain more exposure and attract increased attention and support from scholars in the field.

Figure 11. Photo of Partnership with 3^rd International Conference on Cancer Science and Therapy

Figure 12. Photo of Partnership with 12^th ASIA-PACIFIC BREAST CANCER SUMMIT 2024

Figure 13. 2^nd International Cancer Science Congress

Figure 14. Photo of Partnership with 2^nd Animal Models of Cancer Conference

Figure 15. Photo of Editor-in-Chief Prof. Ciro Isidoro at the 2^nd International Cancer Science Congress (ICSC) 2024

Figure 16. Editor of JCMT at the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) & 4^th International Congress of the Asian Oncology Society (AOS2024)

Figure 17. Editor and Advisory Editor Prof. William C Cho of JCMT at the 2024 China (Guangxi)-Asian International Cancer Precision Medicine Conference

5. Citations

5.1 Indexing

JCMT made significant progress in its academic impact over the past year: achieving its first Impact Factor of 1.4.

5.2 Citation Analysis

In 2024, JCMT gained significant recognition within the global academic community, with 81 citations for articles published in 2022 and 2023, spanning 36 countries and regions. Figure 18 illustrates the distribution of these citations, highlighting JCMT’s broad impact and academic value worldwide. The top 5 countries of the citing authors are China, USA, Germany, Italy, and Japan.

Figure 18. Distribution of citing authors by countries/regions

In addition, we reviewed the quartile distribution of citing journals, as summarized in Figure 19. We are pleased to report that the majority of citations came from journals in the Q1 and Q2 quartiles. The citation counts from the leading Q1 journals are listed in Table 1. We hope that JCMT’s high-quality articles will continue to attract attention and be referenced by scholars in top-tier journals, fostering greater engagement with the academic community.

Figure 19. Quartile distribution of citing journals to JCMT

Table 1. Citing Journals of JCMT in 2024（Q1）

Below are the Top 10 Most Cited Articles (2022-2023) in the journal. We would greatly appreciate your efforts to promote these articles for further impact.

• Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells
  Donald W. Kufe
• The bone marrow niche landscape: a journey through aging, extrinsic and intrinsic stressors in the haemopoietic milieu
  Antonio Giovanni Solimando et al.
• angiogenic drugs in cancer therapeutics: a review of the latest preclinical and clinical studies of anti-angiogenic agents with anticancer potential
  Polyxeni Vafopoulou et al.
• Role of epithelial-mesenchymal transition factor SNAI1 and its targets in ovarian cancer aggressiveness
  Tise Suzuki et al.
• The safety and efficacy of palbociclib in older patients with advanced breast cancer in a real-world setting
  Etienne Gouton et al.
• Biomarkers for therapy selection in metastatic urothelial cancer
  Tomi Jun et al.
• The role of VISTA in the tumor microenvironment
  Dina Rabadi et al.
• Germline predisposition to soft tissue sarcoma
  Jennie Vagher et al.
• Treatment strategies in cervical cancer: treatment of advanced disease
  Augusto Valdivia et al.
• An update on clinical trials for chemoprevention of human skin cancer
  Victoria Jiminez et al.

6. Conclusion and Future Plans

As we reflect on another year gone by, we extend heartfelt gratitude to everyone who has supported and contributed to our journal. We deeply appreciate the trust placed in us with your valuable research and insights. Your groundbreaking work and commitment to academic excellence are the foundation of our publication.

In the coming year, we aim to receive approximately 400 submissions. We also hope to attract around 20 outstanding global scholars to join our Editorial Board, fostering a variety of collaborations. Additionally, the Editorial Office plans to host an online webinar in the first half of the year, participate in two offline meetings, and engage in one online meeting collaboration. Most importantly, JCMT aims to achieve its second Impact Factor 2.5 this June. The Editorial Office will monitor the progress of our published papers and conduct extensive promotional efforts.

In the upcoming months, the Editorial Office of JCMT will continue its tradition of academic excellence while making significant strides toward establishing JCMT as a leading authority in the fields of genetics and genomics. With the unwavering support of all contributors, readers, and the Editorial Board, we are confident that JCMT will achieve these goals and make meaningful contributions to advancing cancer research worldwide.

Managing Editor: Yana Wei
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully submitted by the Editorial Office of Journal of Cancer Metastasis and Treatment